ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
25.07B
Enterprise Value 3
25.72B
Trailing P/E
17.37
Forward P/E 1
9.99
PEG Ratio (5 yr expected) 1
0.67
Price/Sales (ttm)
5.29
Price/Book (mrq)
2.42
Enterprise Value/Revenue 3
5.43
Enterprise Value/EBITDA 6
10.79

Trading Information

Stock Price History

Beta (5Y Monthly) 1.65
52-Week Change 3-1.56%
S&P500 52-Week Change 325.98%
52 Week High 3141.86
52 Week Low 394.59
50-Day Moving Average 3110.50
200-Day Moving Average 3109.36

Share Statistics

Avg Vol (3 month) 31.76M
Avg Vol (10 day) 31.85M
Shares Outstanding 5224.23M
Float 220.74M
% Held by Insiders 10.23%
% Held by Institutions 195.93%
Shares Short (Dec 30, 2019) 44.66M
Short Ratio (Dec 30, 2019) 42.43
Short % of Float (Dec 30, 2019) 42.47%
Short % of Shares Outstanding (Dec 30, 2019) 42.11%
Shares Short (prior month Nov 28, 2019) 44.25M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 22:1
Last Split Date 3May 22, 2011

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq)Sep 29, 2019

Profitability

Profit Margin 31.05%
Operating Margin (ttm)42.73%

Management Effectiveness

Return on Assets (ttm)8.83%
Return on Equity (ttm)15.05%

Income Statement

Revenue (ttm)4.74B
Revenue Per Share (ttm)21.17
Quarterly Revenue Growth (yoy)23.00%
Gross Profit (ttm)3.76B
EBITDA 2.38B
Net Income Avi to Common (ttm)1.47B
Diluted EPS (ttm)6.52
Quarterly Earnings Growth (yoy)41.30%

Balance Sheet

Total Cash (mrq)2.22B
Total Cash Per Share (mrq)10.02
Total Debt (mrq)2.87B
Total Debt/Equity (mrq)27.67
Current Ratio (mrq)3.98
Book Value Per Share (mrq)46.85

Cash Flow Statement

Operating Cash Flow (ttm)1.65B
Levered Free Cash Flow (ttm)1.42B